ERBB2 and gastric cancer: According to the study by Park et al., (2006) on 180 patients with gastric cancer, 15.9% of patients, in which HER-2/neu had been expressed, highly experienced the intestinal type of tumor, and these patients had a shorter five-year survival compared to those without it.